- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01024036
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
February 22, 2018 updated by: Janssen Research & Development, LLC
A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial response) among patients with Multicentric Castleman's Disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double blind (neither investigator nor the participant knows the treatment that the participant receives), placebo controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), study to assess the efficacy and safety of CNTO 328 plus BSC compared with BSC in patients with symptomatic Multicentric Castleman's Disease.
The study mainly consists of 3 phases, including: the screening phase (majority of assessments performed within 28 days of first dose), the treatment phase (blinded and unblinded), and the follow up phase.
In the blinded treatment phase, approximately 78 patients will be randomly assigned in 1:2 ratios to either of 2 treatment groups, ie, Placebo + BSC, or CNTO 328 + BSC.
Participants receiving placebo + BSC during blinded treatment period who do not respond and have treatment failure will have the option to crossover and receive siltuximab + BSC during unbllinded treatent period.
The follow up phase will be 3 months after last dose of study medication and the survival will be followed up until the study ends.
Safety evaluations for adverse events, clinical laboratory tests, electrocardiogram, vital signs, patient-recorded temperature, and physical examination will be monitored throughout the study.
The total study duration will be 5 years after the last patient starts study medication.
Study Type
Interventional
Enrollment (Actual)
79
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
East Melbourne, Australia
-
-
-
-
-
Brussels, Belgium
-
Leuven, Belgium
-
-
-
-
-
Brasilia, Brazil
-
Porto Alegre, Brazil
-
Rio De Janeiro, Brazil
-
Sao Paulo, Brazil
-
-
-
-
-
Toronto, Canada
-
-
-
-
-
Beijing, China
-
Chengdu, China
-
Guangzhou, China
-
Hangzhou, China
-
Shanghai, China
-
-
-
-
-
Cairo, Egypt
-
-
-
-
-
Clermont Ferrand, France
-
Grenoble Cedex 1, France
-
Lille Cedex, France
-
Montpellier, France
-
Paris, France
-
Rennes, France
-
Tours Cedex 9, France
-
Vandoeuvre Les Nancy, France
-
-
-
-
-
Berlin, Germany
-
Mainz, Germany
-
München, Germany
-
-
-
-
-
Sha Tin, Hong Kong
-
-
-
-
-
Budapest, Hungary
-
-
-
-
-
Hyderabad N/A, India
-
Pune, India
-
-
-
-
-
Petach Tikva, Israel
-
Ramat Gan, Israel
-
-
-
-
-
Seoul, Korea, Republic of
-
-
-
-
-
Pandan, Malaysia
-
-
-
-
-
Rotterdam, Netherlands
-
-
-
-
-
Auckland, New Zealand
-
-
-
-
-
Oslo, Norway
-
-
-
-
-
Kazan, Russian Federation
-
Moscow, Russian Federation
-
Saint-Petersburg, Russian Federation
-
St.-Petersburg, Russian Federation
-
-
-
-
-
Singapore, Singapore
-
-
-
-
-
Barcelona, Spain
-
Madrid, Spain
-
-
-
-
-
Taipei, Taiwan
-
-
-
-
-
London, United Kingdom
-
Manchester, United Kingdom
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
-
California
-
Los Angeles, California, United States
-
-
Florida
-
Tampa, Florida, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Lansing, Michigan, United States
-
-
Minnesota
-
Rochester, Minnesota, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
South Carolina
-
Greenville, South Carolina, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Measurable and symptomatic Multicentric Castleman's Disease
- Adequate organ function as assessed by laboratory values evaluated by the investigator to determine eligibility prior to treatment
- Eastern Cooperative Oncology Group performance status of 0, 1, or 2
- Corticosteroids dose that does not exceed 1 mg/kg/day of prednisone, and has remained stable or decreased over the 4 weeks before treatment
Exclusion Criteria:
- Human Immunodeficiency Virus or Human Herpes Virus-8 positive
- Skin lesions as sole measurable manifestation of Multicentric Castleman's Disease
- Previous history of lymphoma
- Malignancies, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or cancer other than lymphoma, from which the patient has been disease-free for 3 or more years
- Concurrent medical condition or disease that may interfere with study participation
- Prior exposure to Interleukin-6 or Interleukin-6 receptor targeted therapies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Siltuximab+best supportive care (BSC)
Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
|
Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
Other Names:
BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
|
Placebo Comparator: Placebo+BSC
Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.
|
BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
Placebo will be administered by 1-hour intravenous infusion every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Achieved Durable Tumor and Symptomatic Response - by Independent Radiology Review
Time Frame: From Day 1 of Cycle 1 of treatment with study medication until treatment failure or discontinuation of treatment or withdrawal from study, or up to 48 weeks after last participant started study medication(approximately 3 years), whichever occurred earlier
|
Durable tumor and symptomatic response is complete response (CR) + partial response (PR).
CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion) and resolution of baseline symptoms attributed to multicentric Castleman's disease, sustained for at least 18 weeks.
PR: >=50 percent decrease in sum of the product of the diameters of indicator lesion(s), with at least stable disease in all other evaluable disease in the absence of treatment failure sustained for at least 18 weeks.
The statistical analysis shows difference in symptomatic response rate (siltuximab+best supportive care [BSC] minus Placebo+BSC).
|
From Day 1 of Cycle 1 of treatment with study medication until treatment failure or discontinuation of treatment or withdrawal from study, or up to 48 weeks after last participant started study medication(approximately 3 years), whichever occurred earlier
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Duration of Tumor and Symptomatic Response - by Independent Radiology Review
Time Frame: From the date when durable tumour and symptomatic response is achieved until treatment failure, as assessed until 48 weeks after the last participant started study treatment (approximately 3 years)
|
Duration of tumor and symptomatic response is defined as time from first documentation of tumor and symptomatic response (CR or PR) to treatment failure.
Whenever possible, treatment failure documented by the appearance of new lesions should be confirmed by histologic examination of the new lesions.
Symptomatic response is complete response (CR) + partial response (PR).
CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion) and resolution of baseline symptoms attributed to multicentric Castleman's disease, sustained for at least 18 weeks.
PR: >=50 percent decrease in sum of the product of the diameters of indicator lesion(s), with at least stable disease in all other evaluable disease in the absence of treatment failure sustained for at least 18 weeks.
|
From the date when durable tumour and symptomatic response is achieved until treatment failure, as assessed until 48 weeks after the last participant started study treatment (approximately 3 years)
|
Percentage of Participants Who Achieved Complete Response (CR) + Partial Response (PR) (Tumor Response Rate) - by Independent Radiology Review
Time Frame: From Day 1 of Cycle 1 until the date when durable tumour and symptomatic response is achieved, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years)
|
Overall tumor response is CR + PR assessed according to Cheson criteria.
CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion).
PR: a >=50 percent decrease in sum of the product of the diameters of index lesion(s), with at least stable disease in all other evaluable disease.
Statistical analysis shows difference of overall response rates (siltuximab+best supportive care [BSC] minus Placebo+BSC).
|
From Day 1 of Cycle 1 until the date when durable tumour and symptomatic response is achieved, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years)
|
Median Duration of Tumor Response - by Independent Radiology Review
Time Frame: From the date when tumour response is achieved until tumour progression, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years)
|
Duration of tumor response is defined as time from first documentation of tumor response to tumor progression.
Tumour response is complete response (CR) + partial response (PR) as assessed according to Cheson criteria.
CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion).
PR: a >=50 percent decrease in sum of the product of the diameters of index lesion(s), with at least stable disease in all other evaluable disease.
Statistical analysis shows difference of overall response rates (siltuximab+best supportive care [BSC] minus Placebo+BSC).
|
From the date when tumour response is achieved until tumour progression, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years)
|
Time to Treatment Failure
Time Frame: From the date of randomization until a participant fails treatment, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years), whichever occurred earlier
|
Time to treatment failure was defined as the time from randomization until the participant fails treatment.
Treatment failure was defined as any of the following: a sustained increase from baseline in disease related symptoms >=Grade 2 persisting for at least 3 weeks despite best supportive care (BSC); onset of any new disease related Grade 3 or higher symptom despite BSC; sustained (ie, at least 3 weeks) deterioration in performance status (increase from baseline in Eastern Cooperative Oncology Group Performance Status by more than 1 point) despite BSC; radiologic progression, as measured by modified Cheson criteria; Initiation of any other therapy intended to treat multicentric Castleman's disease ie, prohibited treatments.
Statistical analysis shows difference in treatment failure rate (siltuximab+BSC minus Placebo+BSC).
|
From the date of randomization until a participant fails treatment, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years), whichever occurred earlier
|
Percentage of Participants Who Achieved Greater Than or Equal to (>=) 15 Gram Per Liter (g/L) Hemoglobin at Week 13 (Hemoglobin Response Rate)
Time Frame: Week 13
|
Hemoglobin response rate is defined as percentage of participants who achieved >= 15 g/L hemoglobin at Week 13.
|
Week 13
|
Percentage of Participants Who Achieved >= 20 g/L Hemoglobin at Week 13 (Hemoglobin Response Rate)
Time Frame: Week 13
|
Hemoglobin response rate is defined as percentage of participants who achieved >= 20 g/L hemoglobin at Week 13.
|
Week 13
|
Percentage of Participants Who Discontinued Corticosteroids
Time Frame: From Day 1 of Cycle 1 until 48 weeks after the after the last participant started study treatment (approximately 3 years)
|
Percentage of participants who discontinued corticosteroids during blinded treatment period and who were dependent on corticosteroids at baseline (Day 1 of Cycle 1).
|
From Day 1 of Cycle 1 until 48 weeks after the after the last participant started study treatment (approximately 3 years)
|
6-year Survival Rate
Time Frame: until 6 years
|
Overall survival was defined as percent chance of survival of participants who were still alive at 6 years from time of first study treatment was analyzed.
|
until 6 years
|
Median Time Required to Achieve >=1 Point Decrease in the Multicentric Castleman's Disease Symptom Scale (MCD-SS) Score From Baseline
Time Frame: From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)
|
A patient-reported symptom scale.
Symptom presence/absence and severity are noted on an anchor-based numeric scale.
Scores range from 1 (very mild) to 5 (very severe).
|
From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)
|
Median Time Required to Achieve >=3-point Increase in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores From Baseline
Time Frame: From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)
|
The FACIT-F, a 13-item instrument, was designed to measure patient-reported fatigue.
It is one of the suite of FACIT instruments developed for outcomes in cancer.
Concepts measured in the scale include tiredness, weakness, and difficulty conducting usual functional activities or social interaction due to fatigue.
Response options range from "not at all" (0) to "very much" (4), and yield a summary score.
Total FACIT-F score is the sum of 13 items, ranging from 0 (not at all) to 52 (very much).
Higher scores represent better outcomes.
|
From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)
|
Median Time Required to Achieve >=5-point Increase in the Short-Form-36 (SF-36) Physical Component Summary (PCS) Scores From Baseline
Time Frame: From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)
|
SF-36 is a questionnaire and PCS is a part of subscale assessing physical functioning, role-physical, bodily pain, and general health.
The scores range from 0 (worst score) to 100 (best score), with a higher score indicating better quality of life.
|
From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, Fajgenbaum DC. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022 Aug 23;6(16):4773-4781. doi: 10.1182/bloodadvances.2022007112.
- Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fossa A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 Mar 23;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933. Epub 2017 Jan 13.
- van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Erratum In: Lancet Oncol. 2014 Sep;15(10):417.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 18, 2010
Primary Completion (Actual)
March 25, 2013
Study Completion (Actual)
February 24, 2017
Study Registration Dates
First Submitted
November 30, 2009
First Submitted That Met QC Criteria
December 1, 2009
First Posted (Estimate)
December 2, 2009
Study Record Updates
Last Update Posted (Actual)
March 21, 2018
Last Update Submitted That Met QC Criteria
February 22, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR016705
- CNTO328MCD2001 (Other Identifier: Janssen Research & Development, LLC)
- 2009-012380-34 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multicentric Castleman's Disease
-
EusaPharma (UK) LimitedTerminatedIdiopathic Multicentric Castleman's DiseaseUnited States
-
EusaPharma (UK) LimitedUniversity of Sheffield (ScHARR); KMC Health Care; Castleman Disease Collaborative...Not yet recruitingIdiopathic Multicentric Castleman's Disease
-
Beijing VDJBio Co., LTD.RecruitingIdiopathic Multicentric Castleman's DiseaseChina
-
Peking Union Medical College HospitalRecruitingZanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial (iMCD)Idiopathic Multicentric Castleman's DiseaseChina
-
Peking Union Medical College HospitalRecruitingIdiopathic Multicentric Castleman's DiseaseChina
-
Hoffmann-La RocheCompleted
-
University of PennsylvaniaRecruitingCastleman Disease | Castleman's Disease, MulticentricUnited States
-
Peking Union Medical College HospitalUnknownMulticentric Castleman DiseaseChina
-
UNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of HealthRecruitingMulticentric Castleman DiseaseMalawi
-
Janssen Research & Development, LLCCompletedMulticentric Castleman's DiseaseUnited States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Israel, Korea, Republic of, Singapore, Brazil, Belgium, New Zealand, Norway, Egypt, Hong Kong
Clinical Trials on Siltuximab
-
Carla Greenbaum, MDJanssen Research & Development, LLCCompleted
-
Centocor, Inc.CompletedLymphoma, Non-Hodgkin | Multiple Myeloma | Giant Lymph Node HyperplasiaUnited States
-
University of Alabama at BirminghamRecruitingLymphoma, Non-Hodgkin | Multiple Myeloma | Acute Lymphoblastic Leukemia | Cytokine Release Syndrome | ICANSUnited States
-
Janssen Research & Development, LLCCompletedHigh-risk Smoldering Multiple MyelomaUnited States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
-
Janssen Research & Development, LLCCompletedMultiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell NeoplasmUnited States, Belgium, Russian Federation
-
Janssen Research & Development, LLCCompletedMulticentric Castleman's DiseaseUnited States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Israel, Korea, Republic of, Singapore, Brazil, Belgium, New Zealand, Norway, Egypt, Hong Kong
-
Centocor, Inc.Completed
-
EusaPharma (UK) LimitedTerminatedIdiopathic Multicentric Castleman's DiseaseUnited States
-
Centocor, Inc.CompletedCarcinoma, Renal CellFrance, United Kingdom, Netherlands, Czech Republic
-
Janssen Research & Development, LLCTerminatedMyelodysplastic SyndromeUnited States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation